Gastroenterological Surgery: Esophagus

Kitagawa, Yuko; Ichikawa, Hitoshi; Inoue, Haruhiro; Udagawa, Harushi; Uyama, Ichiro; Osugi, Harushi; Katada, Natsuya; Takeuchi, Hiroya; Akutsu, Yasunori; Asami, Shinya; Ishikawa, Ken; Okamura, Akihiko; Ono, Taiki; Kato, Fumihiko; Kawabata, Toshiki; Suda, Kenichi; Takesue, Tomoko; Tanaka, Tsuyoshi; Tsutsui, Mai; Hosoda, Kei; Matsuda, Satoru; Matsuda, Tatsuo; Man-i, Mariko; Miyazaki, Tatsuya

doi:10.1111/ases.12185

Cited by 3 publications

(2 citation statements)

References 81 publications

(175 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is considered that esophagectomy is the main strategy for esophageal cancer; however, the survival benefit with surgery alone is unsatisfactory, and the survival rates have been reported to be about 20%–30% at 2 years [ 1 ] and 10%–20% at 5 years [ 2 ]. In Western countries, neoadjuvant chemoradiotherapy is a standard treatment for resectable esophageal cancer [ 3 – 5 ]. In Japan, a randomized phase III trial (JCOG9204) showed that disease-free survival with adjuvant chemotherapy (AC) involving cisplatin/5-fluorouracil (5-FU) therapy (CF) was superior to that with surgery alone.…”

Section: Introductionmentioning

confidence: 99%

A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer

et al. 2017

View full text Add to dashboard Cite

BackgroundRecently, neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil (NAC-DCF) was identified as a novel strong regimen with a high rate of pathological complete response (pCR) in advanced esophageal cancer in Japan. Predicting pCR will contribute to the therapeutic strategy and the prevention of surgical invasion. However, a predictor of pCR after NAC-DCF has not yet been developed. The aim of this study was to identify a novel predictor of pCR in locally advanced esophageal cancer treated with NAC-DCF.Patients and methodsA total of 32 patients who received NAC-DCF followed by esophagectomy between June 2013 and March 2016 were enrolled in this study. We divided the patients into the following 2 groups: pCR group (9 cases) and non-pCR group (23 cases), and compared gene expressions between these groups using DNA microarray data and KeyMolnet. Subsequently, a validation study of candidate molecular expression was performed in 7 additional cases.ResultsSeventeen molecules, including transcription factor E2F, T-cell-specific transcription factor, Src (known as “proto-oncogene tyrosine-protein kinase of sarcoma”), interferon regulatory factor 1, thymidylate synthase, cyclin B, cyclin-dependent kinase (CDK) 4, CDK, caspase-1, vitamin D receptor, histone deacetylase, MAPK/ERK kinase, bcl-2-associated X protein, runt-related transcription factor 1, PR domain zinc finger protein 1, platelet-derived growth factor receptor, and interleukin 1, were identified as candidate molecules. The molecules were mainly associated with pathways, such as transcriptional regulation by SMAD, RB/E2F, and STAT. The validation study indicated that 12 of the 17 molecules (71%) matched the trends of molecular expression.ConclusionsA 17-molecule set that predicts pCR after NAC-DCF for locally advanced esophageal cancer was identified.

show abstract

Section: Introductionmentioning

confidence: 99%

A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Oesophagectomy is a complex surgical procedure. Despite improvements in surgical techniques and perioperative treatments, it is still associated with severe postoperative complications and a high risk of mortality. Several studies have reported that patients undergoing oesophagectomy in high‐volume hospitals experience a lower mortality rate.…”

Section: Introductionmentioning

confidence: 99%